ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
 PMID: 18651855       2008       HIV medicine
Abstract: RESULTS: At the time of VF, RAL-resistance mutations were selected: (i) Q148R in patients 1 and 3; (ii) T66A and E92Q in patient 2.


  Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
 PMID: 18687142       2008       Retrovirology
Result: Among the CCD mutations shown to directly reduce raltegravir or elvitegravir susceptibility - H51Y, T66I, E92Q, F121Y, G140S, Y143C/H/R, Q146P, S147G, Q148H/R/K, S153Y, N155H/S, and E157Q - only positions 153 and 157 are polymorphic (prevalence >= 0.5%) with S153A and E157Q each present in 1% of sequences (Figures 1).
Discussion: Nearly all INI-resistance mutations known to directly reduce HIV-1 susceptibility were nonpolymorphic i


  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
 PMID: 18702518       2008       Biochemistry
Abstract: The aims of the present study were (1) to investigate and compare the effects of raltegravir and elvitegravir on the th
Figure: Deferential effect of the E92Q integrase mutation on inhibition of 3'-processing vs.
Figure: Gel image of the inhibition of HIV-1 integrase E92Q by raltegravir using both protocols.


  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
 PMID: 18715920       2008       Journal of virology
Abstract: We find the primary resistance-conferring mutations to be Q148R, E92Q, and T66I and demonstrate that they confer a reduction in susceptibility not only to elvitegravir but also to raltegravir (MK-0518) and other integrase inhibitors.


  [Resistance to integrase inhibitors].
 PMID: 19572425       2008       Enfermedades infecciosas y microbiologia clinica
Abstract: Less frequently, Y143R (6.6%) and E92Q are selected.
Abstract: The most frequently observed mutations in failure with elvitegravir are E92Q, E138K, Q148R/K/H and N155H, and less frequently S147G and T66A/I/K.



Browser Board

 Co-occurred Entities




   Filtrator